Vimarsana
Biggest News Aggregation in the World

Acetamides News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acetamides. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acetamides Today - Breaking & Trending Today

Melatonin use in children: Is a sleep aid supplement safe? - Vimarsana News

Melatonin use in children: Is a sleep aid supplement safe?

Melatonin is a hormone naturally produced in the brain that's linked to your body's sleep and wake cycle. The natural release of melatonin is stimulated by darkness and suppressed by

How much melatonin is in gummies? - Vimarsana News

How much melatonin is in gummies?

A study found the quantities of melatonin typically wildly exceed what is stated in labels

Source: qz.com
What Happens If You Take Too Much Melatonin? - Vimarsana News

What Happens If You Take Too Much Melatonin?

Does your "3 mg" gummy actually contain 10 milligrams of melatonin? According to a recent study, it might.

Shilpa Medicare gets USFDA nod for arthritis drug - Vimarsana News

Shilpa Medicare gets USFDA nod for arthritis drug

Shilpa Medicare has received United States Food and Drug Administration (USFDA)'s tentative approval for its abbreviated new drug application (ANDA), apremilast tablets, 10 mg, 20 mg, and 30 mg. The ANDA was filed as 'First to File' submission on NCE -1 date to seek eligibility for 180 days exclusivity. Apremilast tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene, used in the treatment of 'psoriatic arthritis' as recommended in the label approved by FDA. According to IQVIA MAT Q2 2020 data, the US market for apremilast tablets, 10 mg, 2...

Alembic Pharma rises after USFDA nod for orthostatic hypotension drug - Vimarsana News

Alembic Pharma rises after USFDA nod for orthostatic hypotension drug

Alembic Pharmaceuticals gained 0.59% to Rs 956.4 after the drug maker received the US drug regulator's approval for midodrine hydrochloride tablets.Alembic Pharmaceuticals (Alembic) on 22 January 2020 announced that it received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) midodrine hydrochloride tablets USP, 2.5 mg, 5 mg, and 10 mg. The drug is indicated for the treatment of symptomatic orthostatic hypotension (OH). The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), ProAmatine tablets of Takeda...